Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biohaven Pharmaceutical Holding Ltd (BHVN)

Biohaven Pharmaceutical Holding Ltd (BHVN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,312,177
  • Shares Outstanding, K 65,074
  • Annual Sales, $ 63,630 K
  • Annual Income, $ -766,800 K
  • 60-Month Beta 1.01
  • Price/Sales 97.15
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BHVN with:

Options Overview

Details
  • Implied Volatility 63.91%
  • Historical Volatility 49.39%
  • IV Percentile 27%
  • IV Rank 25.15%
  • IV High 125.63% on 01/05/21
  • IV Low 43.16% on 05/28/21
  • Put/Call Vol Ratio 0.41
  • Today's Volume 316
  • Volume Avg (30-Day) 744
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 22,071
  • Open Int (30-Day) 19,275

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -3.28
  • Number of Estimates 5
  • High Estimate -2.63
  • Low Estimate -3.82
  • Prior Year -2.55
  • Growth Rate Est. (year over year) -28.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
76.83 +26.50%
on 05/24/21
106.57 -8.79%
on 06/11/21
+18.05 (+22.80%)
since 05/21/21
3-Month
62.57 +55.35%
on 03/30/21
106.57 -8.79%
on 06/11/21
+24.99 (+34.61%)
since 03/22/21
52-Week
57.66 +68.57%
on 08/11/20
106.57 -8.79%
on 06/11/21
+23.51 (+31.90%)
since 06/22/20

Most Recent Stories

More News
Biohaven Appoints Kishen Mehta to Board of Directors

/PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced the appointment of , Portfolio Manager at Suvretta Capital Management, LLC, to its Board of Directors ("Board")....

BHVN : 97.20 (+0.21%)
New Strong Sell Stocks for June 14th

CPB, MLAB, TMQ, CGAU, and BHVN have been added to the Zacks Rank #5 (Strong Sell) List on June 14, 2021

CPB : 45.59 (+0.09%)
MLAB : 264.01 (+0.66%)
BHVN : 97.20 (+0.21%)
TMQ : 2.54 (+6.72%)
CGAU : 8.01 (+1.26%)
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 35.3% Since Last Earnings Report: Can It Continue?

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BHVN : 97.20 (+0.21%)
Photo of Biohaven Pharmaceuticals Ringing the Opening Bell Available on Business Wire's Website and the Associated Press Photo Network

A photo is available on Business Wire's website and the Associated Press Photo Network of Biohaven Pharmaceuticals (NYSE: BHVN) ringing the opening bell, June 8, 2021. BJ Jones, Chief Commercial Officer,...

BHVN : 97.20 (+0.21%)
Biohaven Showcases CGRP-Antagonist Franchise Data including Nurtec® ODT (rimegepant), Now Approved to Treat and Prevent Migraine Attacks, and Zavegepant with 19 Presentations at the 2021 Virtual Annual Scientific Meeting of the American Headache Society

, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that 19 abstracts, including one late-breaking presentation and two oral presentations, will be presented...

BHVN : 97.20 (+0.21%)
Biohaven's (BHVN) Nurtec Gets FDA Nod for Migraine Prevention

The FDA approves Biohaven's (BHVN) Nurtec ODT to prevent migraine besides treating acute migraine attacks.

LLY : 221.44 (-0.55%)
AMGN : 239.91 (-0.14%)
ABBV : 114.70 (-0.03%)
BHVN : 97.20 (+0.21%)
FDA Approves Biohaven's NURTEC® ODT (rimegepant) for Prevention: Now the First and Only Migraine Medication for both Acute and Preventive Treatment

, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that the U.S. Food and Drug Administration (FDA) has approved NURTEC® ODT (rimegepant 75 mg) for the preventive...

BHVN : 97.20 (+0.21%)
New Strong Sell Stocks for May 24th

ANIP, BHVN, FVRR, KBAL, and PLNT have been added to the Zacks Rank #5 (Strong Sell) List on May 24, 2021

ANIP : 33.16 (-1.37%)
PLNT : 77.07 (+1.25%)
KBAL : 13.11 (-1.28%)
BHVN : 97.20 (+0.21%)
FVRR : 230.99 (+1.33%)
Biohaven's Nurtec® ODT Signs as Primary Partner with Rick Ware Racing for 2021 NTT INDYCAR Series Program

, /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Nurtec® ODT (rimegepant) will be the primary partner for the Rick Ware Racing No. 51 NTT IndyCar Series program. Nurtec ODT's...

BHVN : 97.20 (+0.21%)
Biohaven (BHVN) Q1 Earnings Miss, Nurtec Uptake Remains Strong

Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.

LLY : 221.44 (-0.55%)
AMGN : 239.91 (-0.14%)
ABBV : 114.70 (-0.03%)
BHVN : 97.20 (+0.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which...

See More

Key Turning Points

3rd Resistance Point 102.78
2nd Resistance Point 100.93
1st Resistance Point 99.07
Last Price 97.20
1st Support Level 95.36
2nd Support Level 93.51
3rd Support Level 91.65

See More

52-Week High 106.57
Last Price 97.20
Fibonacci 61.8% 87.88
Fibonacci 50% 82.11
Fibonacci 38.2% 76.34
52-Week Low 57.66

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar